SAN

83.34

+0.43%↑

MRK1

111.25

-0.22%↓

SHL.DE

47.42

+1.22%↑

ARGX

464.9

+0.5%↑

FRE

42.32

+0.93%↑

SAN

83.34

+0.43%↑

MRK1

111.25

-0.22%↓

SHL.DE

47.42

+1.22%↑

ARGX

464.9

+0.5%↑

FRE

42.32

+0.93%↑

SAN

83.34

+0.43%↑

MRK1

111.25

-0.22%↓

SHL.DE

47.42

+1.22%↑

ARGX

464.9

+0.5%↑

FRE

42.32

+0.93%↑

SAN

83.34

+0.43%↑

MRK1

111.25

-0.22%↓

SHL.DE

47.42

+1.22%↑

ARGX

464.9

+0.5%↑

FRE

42.32

+0.93%↑

SAN

83.34

+0.43%↑

MRK1

111.25

-0.22%↓

SHL.DE

47.42

+1.22%↑

ARGX

464.9

+0.5%↑

FRE

42.32

+0.93%↑

Search

Orion Oyj (Class B)

Slēgts

65.3 -0.68

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

63.9

Max

67.05

Galvenie mērījumi

By Trading Economics

Ienākumi

-12M

61M

Pārdošana

-80M

355M

P/E

Sektora vidējais

25.565

39.564

EPS

0.44

Dividenžu ienesīgums

2.57

Peļņas marža

17.287

Darbinieki

3,943

EBITDA

202M

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

2.57%

2.40%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

3.4B

8.9B

Iepriekšējā atvēršanas cena

65.98

Iepriekšējā slēgšanas cena

65.3

Orion Oyj (Class B) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 9. jūl. 15:46 UTC

Galvenie tirgus virzītāji

BitMine Shares Fall After Closing of $250 Million Private Placement

2025. g. 9. jūl. 23:44 UTC

Tirgus saruna

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

2025. g. 9. jūl. 23:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 9. jūl. 23:42 UTC

Tirgus saruna

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

2025. g. 9. jūl. 22:59 UTC

Tirgus saruna

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

2025. g. 9. jūl. 22:59 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 9. jūl. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 9. jūl. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. jūl. 20:26 UTC

Peļņas

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

2025. g. 9. jūl. 19:18 UTC

Tirgus saruna

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

2025. g. 9. jūl. 19:03 UTC

Tirgus saruna

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

2025. g. 9. jūl. 18:31 UTC

Tirgus saruna

Some Fed Officials Supported Considering July Cut -- Market Talk

2025. g. 9. jūl. 17:07 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

2025. g. 9. jūl. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk -2-

2025. g. 9. jūl. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 9. jūl. 16:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 9. jūl. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. jūl. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 9. jūl. 16:14 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 9. jūl. 16:14 UTC

Tirgus saruna

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

2025. g. 9. jūl. 16:14 UTC

Iegādes, apvienošanās, pārņemšana

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

2025. g. 9. jūl. 16:12 UTC

Tirgus saruna

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

2025. g. 9. jūl. 16:08 UTC

Tirgus saruna

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

2025. g. 9. jūl. 15:31 UTC

Galvenie tirgus virzītāji

BitMine Shares Fall After Closing of $250M Private Placement

2025. g. 9. jūl. 15:31 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

2025. g. 9. jūl. 15:27 UTC

Tirgus saruna

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

2025. g. 9. jūl. 14:36 UTC

Iegādes, apvienošanās, pārņemšana

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

2025. g. 9. jūl. 14:31 UTC

Iegādes, apvienošanās, pārņemšana

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

2025. g. 9. jūl. 14:26 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 9. jūl. 14:26 UTC

Tirgus saruna

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Salīdzinājums

Cenas izmaiņa

Orion Oyj (Class B) Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.